PodParley PodParley
PodParley
Dasher Neuroscience's Phase 2 Enrollment Complete: AI-driven CNS drug ahead to readout — promise tempered by typical small‑cap biotech risks episode artwork

EPISODE · Jul 28, 2026 · 9 MIN

Dasher Neuroscience's Phase 2 Enrollment Complete: AI-driven CNS drug ahead to readout — promise tempered by typical small‑cap biotech risks

from Alpha Casts - AI Market Intelligence

Dasher Neuroscience (TPEx: 7829) announced completion of patient enrollment in its global Phase 2 trial of YA-101 for Multiple System Atrophy (MSA). The milestone validates an operational execution step for an AI‑discovered CNS candidate but leaves efficacy, safety and commercial pathway unresolved until readouts and regulatory interactions.

Episode metadata supplied by the publisher feed · Published Jul 28, 2026

Embed this episode

NOW PLAYING

Dasher Neuroscience's Phase 2 Enrollment Complete: AI-driven CNS drug ahead to readout — promise tempered by typical small‑cap biotech risks

0:00 9:16

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Alpha Casts - AI Market Intelligence?

This episode is 9 minutes long.

When was this Alpha Casts - AI Market Intelligence episode published?

This episode was published on July 28, 2026.

Can I download this Alpha Casts - AI Market Intelligence episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!